Dr Michael Serzan, medical oncologist at the Dana-Farber Cancer Institute, Boston, MA was so kind to summarize the outcomes of the CLEAR and CONTACT studies in renal cell carcinoma and concludes with the impact of these data on current and future clinical practice. The efficacy and safety of atezolizumab and cabozantinib after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma was evaluated in the CONTACT-03 study. The final prespecified overall survival analysis of the CLEAR study shows that the combination of lenvatinib and pembrolizumab continues to demonstrate clinically meaningful benefit versus sunitinib as first line treatment of patients with advanced renal cell carcinoma at 4-year follow-up.
With the educational support of:
